CagriSema vs Semaglutide
CagriSema is semaglutide with an amylin analog added in the same weekly shot; the question is whether the second pathway earns its place, and it is not approved.
CagriSema
~20% in REDEFINE 1; amylin plus GLP-1 in one shot — promising, not yet approved.
Full CagriSema evidence reviewSemaglutide
Wegovy / Ozempic
~15% mean weight loss in STEP 1; the benchmark that opened modern obesity medicine.
Full Semaglutide evidence reviewSide by side
| CagriSema | Semaglutide | |
|---|---|---|
| Marketed for | Weight loss | Weight loss, type-2 diabetes |
| Evidence grade | Clinical data | FDA-approved |
| Family | GLP-1 / incretin | GLP-1 / incretin |
| Regulatory status | Investigational | FDA-approved |
| How it's obtained | Research-only | Rx product |
| Key human source | REDEFINE 1, NEJM 2025 | STEP 1, NEJM 2021 |
marks a row where the two differ. Evidence grades come from our evidence matrix, which grades each molecule on the human data for the use it is marketed for.
Our verdict
Semaglutide is approved and has the deeper record: about 14.9% mean weight loss in STEP 1, the STEP 4 data showing substantial regain after stopping, and a roughly 20% reduction in major adverse cardiovascular events in SELECT. CagriSema reported about 20% in REDEFINE 1 and also beat placebo in REDEFINE 2, but it is investigational, has no long-term cardiovascular outcomes evidence, and its topline landed below pre-trial expectations, partly because many participants did not reach the highest target dose. REDEFINE 1 did randomize against the individual components as well as placebo, which makes it the closest thing to a direct read in this pair.
CagriSema fits if
You are watching whether pairing amylin with GLP-1 becomes an approved option, and you read Phase 3 data before it reaches the clinic.
Semaglutide fits if
You want a GLP-1 that can actually be prescribed, with hard cardiovascular outcome evidence behind it.